Special Issue "Apoptosis in Cancer"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: 31 August 2019
Prof. Arun Dharmarajan
School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute (CHIRI), Curtin University, Perth, Western Australia, Australia
Website | E-Mail
Interests: wnt signaling, secreted frizzled related protein 4, cancer, cancer stem cells, angiogenesis, apoptosis, redox signaling, molecular modelling
In the last decade, basic cancer research has produced remarkable advances in our understanding of cancer biology and cancer genetics. Among the most important of these advances is the realization that apoptosis and the genes that control it have a profound effect on the malignant phenotype. For example, it is now clear some oncogenic mutations disrupt the apoptotic process leading to tumor initiation, progression, and finally metastasis. It is now well documented that most cytotoxic anticancer agents induce apoptosis, raising the intriguing possibility that deregulation in apoptotic programs contributes to treatment failure. Apoptosis is mechanistically governed through two main pathways; the extrinsic (death receptor-mediated) and the intrinsic, or the mitochondrial pathway which is activated in response to cellular damage induced through radiation, hypoxia, and some anti-cancer agents. Dysregulation of these apoptotic pathways can result in the resistance of cell death, and is a hallmark of cancer. Consequently, targeting key regulatory proteins within these pathways has been a primary focus of many cancer studies. A prototypical example of this is the targeting of B-cell lymphoma 2 (BCL-2) family of proteins. The primary focus of this topic will be cell signaling in apoptosis, mitochondrial-mediated apoptosis, novel compounds to target apoptosis and cancer. In addition, the reviews and research articles will explore the mechanisms of apoptosis and the ways in which tumor cells modulate these processes to induce their survival and examine current clinical modalities aimed at exploiting these defects to selectively induce apoptosis in tumor cells.
Prof. Arun Dharmarajan
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Redox signaling